New RA Antibody Treatment
SAN DIEGO—A recent study examined the pharmacokinetics, safety and efficacy of E6011, an anti-fractalkine monoclonal antibody designed to treat rheumatoid arthritis (RA).1 Researchers presented the results of this first 52-week trial of E6011 at the 2017 ACR/ARHP Annual Meeting in November. Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CXCR1)-expressing inflammatory cells.
During the study’s treatment phase, Japanese patients with active RA who had an inadequate response or intolerance to methotrexate or tumor necrosis factor-alpha inhibitors received E6011 at Weeks 0, 1 and 2, and every two weeks thereafter for up to 10 weeks. Patients received 100 mg (n=12), 200 mg (n=15) or 400 mg (n=10) doses.
If the agent showed no safety concerns, patients who had a greater than 20% improvement in both tender and swollen joint counts were given the option to receive an additional 20 biweekly treatments at the same dose in an extension phase. Of these 37 patients, 11 patients treated with 100 mg, 11 patients treated with 200 mg and 6 patients treated with 400 mg entered the extension phase, which lasted 52 weeks.